A UK-based KOL discusses the current gastric cancer treatment landscape within the NHS, highlighting the significant access and reimbursement barriers that distinguish UK practice from the US and other European markets. The KOL provides insight into the perioperative chemotherapy landscape before and in anticipation of durvalumab reimbursement, first- and later-line treatment approaches including the role of zolbetuximab and checkpoint inhibitors, and future directions including zanidatamab, CAR-T therapies, and emerging ADC and bispecific approaches.

This interview was conducted on April 10, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.